Antiangiogenic and antimetastatic properties of Neovastat (Æ-941), an orally active extract derived from cartilage tissue

Clinical and Experimental Metastasis

Volumn 19, Issue 2, 2002, Pages 145-153

  Dupont, Áric ^a   Falardeau, Pierre ^a   Mousa, Shaker A ^b   Dimitriadou, Violetta ^a   Pepin, Marie Claude ^a   Wang, Taiqi ^c   Alaoui Jamali, Moulay A ^c  

^a Les Laboratoires Æterna Inc 1405   (Canada)

^b DUPONT COMPANY   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

941; Antiangiogenesis; Antimetastases; Cartilage extract; Cartilage tissue; Cisplatinum; Neovastat

Indexed keywords

AE 941; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; CISPLATIN; HEMOGLOBIN; MATRIGEL;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; BONE MARROW SUPPRESSION; CANCER GROWTH; CARTILAGE; CHORIOALLANTOIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HUMAN CELL; LUNG CARCINOMA; LUNG METASTASIS; METASTASIS INHIBITION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; TREATMENT PLANNING; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD VESSELS; BODY WEIGHT; CARCINOMA, LEWIS LUNG; CARTILAGE; CHICK EMBRYO; CISPLATIN; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LAMININ; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; TISSUE EXTRACTS;

EID: 0036211156     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014546909573     Document Type: Article

References (50)

1. Angiogenesis
2. Angiogenesis: New aspects relating to its initiation and control
3. Mechanisms of angiogenesis in vascular disorders: Potential therapeutic targets
4. A highly conserved vascular permeability factor secreted by a variety of human and rodent cell lines
5. Purification of a vascular permeability factor (VPF) from tumor cell conditioned medium
6. Purification from a human hepatoma cell line of a basic FGF-like molecule that stimulates capilary endothelial cell plasminogen activator production, DNA synthesis and migration
7. Fibroblast growth factors: Broad spectrum mitogens with potent angiogenic activity
8. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
9. Angiostatin induces and sustains dormancy of human primary tumors in mice
10. Anti-angiogenesis: New concept for therapy of solid tumors
11. Angiogenesis: Mechanistic insights, neovascular diseases, and therapeutic prospects
12. Angiogenesis in cancer, vascular, rheumatoid and other disease
13. Anti-angiogenesis: A multipurpose therapeutic tool?
14. Acquired multicellular-mediated resistance to alkylating agents in cancer
15. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo
16. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
17. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
18. Vascular attack as a therapeutic strategy for cancer
19. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
20. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies
21. Inhibition of tumor angiogenesis mediated by cartilage
22. Isolation of a cartilage factor that inhibits tumor neovascularization
23. Shark cartilage contains inhibitors of tumor angiogenesis
24. Identification of an inhibitor of neovascularization from cartilage
25. A novel angiogenic inhibitor derived from Japanese shark cartilage (1). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis
26. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and antitumor activities
27. Troponin I is present in human cartilage and inhibits angiogenesis
28. Cartilage as a source of natural inhibitors of angiogenesis
29. Mammary tumorigenesis in chemical carcinogen-treated mice. VI. Tumor-producing capabilities of mammary dysplasias in Ba1b/cCrg1 mice
30. Characterization of two highly metastatic variants of Lewis lung carcinoma with different organ specificities
31. Novel small molecule AV integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors
32. Kinetic parameters and growth curves for experimental tumor systems
33. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound
34. Characterization of collagenase, other metalloproteinases and an inhibitor (TIMP) produced by human synovium and cartilage in culture
35. Purification and partial amino acid sequence of bovine cartilage-derived collagenase inhibitor
36. Association of collagenase and tissue inhibitor of metalloproteinases (TIMP) with hypertrophic cell enlargement in the growth plate
37. Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes
38. Purification of an angiogenesis inhibitor from culture medium conditioned by a human chondrosarcoma-derived chondrocytic cell line, HCS-2/8
39. The resistance of certain tissue to invasion. III. Cartilage extracts inhibit the growth of fibroblasts and endothelial cells in culture
40. Morphological studies on the resistance of cartilage to invasion by osteosarcoma cells in vitro and in vivo
41. Resistance of cartilage to invasion
42. Cartilage-derived anti-tumor factor (CAFT) inhibits the proliferation of endothelial cells in culture
43. Inhibition of angiogenesis by oral ingestion of powdered shark cartilage in a rat model
44. In vivo antitumoral activity of the multifunctional antiangiogenic agent neovastat in experimental glioma
45. Tumor angiogenesis - New drugs on the block
46. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: Effects on tumor neovascularization
47. Potentiation of cytotoxic cancer therapies by antiangiogenic agents
48. Phase I/II clinical trials of escalating dose of AE-941, an inhibitor of angiogenesis in patients with refractory lung cancer